Apteryx Imaging vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dental imaging and practice management software for small and mid-size dental practices, offering digital radiography, patient records, and imaging workflow tools. Based in Akron, Ohio.
About
Apteryx Imaging is an Akron, Ohio-based dental technology company specializing in digital radiography software and imaging workflow tools for dental practices. The company developed XrayVision, a widely used dental imaging software platform that supports intraoral sensors, phosphor plate systems, and panoramic units from multiple hardware manufacturers. This hardware-agnostic approach differentiates Apteryx from imaging vendors that bundle proprietary sensor hardware with locked-in software.\n\nXrayVision integrates with a broad range of practice management and electronic dental record systems, allowing practices to retain their existing clinical software while upgrading or adding digital imaging hardware from various manufacturers. The platform includes tools for image acquisition, enhancement, annotation, and archiving, as well as periodontal charting and patient communication features that extend its utility beyond pure radiography management.\n\nApteryx has been acquired by Carestream Dental, becoming part of a broader dental imaging portfolio. Prior to the acquisition, Apteryx built a loyal installed base among independent dental practices and small group practices that valued the flexibility of working with multiple sensor brands rather than being locked into a single manufacturer's ecosystem. The company's strength in open imaging platform integrations has historically made it popular with practices that prioritize interoperability and want the freedom to choose imaging hardware independently from their software platform.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.